-
Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations
Sep 9, 2025, 16:22 PM -
Signal Detection and Network Pharmacology Analysis of Paronychia Associated With eGFR Inhibitors
Sep 9, 2025, 16:22 PM -
Economic and Epidemiological Burden of Type 1 Diabetes In France
Sep 9, 2025, 16:22 PM -
Life-Years Lost Due to Regulatory and Reimbursement Delays: A Study of Oncology Drugs Across England, Scotland, and France, 2022-2024
Sep 9, 2025, 16:22 PM -
Differential Responsiveness and Minimally Important Difference of EQ-5D: Truth or Artifact?
Sep 9, 2025, 16:22 PM -
The Role of Real-World Evidence in Health Technology Assessment Decision Making
Sep 9, 2025, 16:22 PM -
Barriers and Facilitators of Antiepileptic Drug Adherence: A Qualitative Study Among People Living With Epilepsy in Pakistan
Sep 9, 2025, 16:22 PM -
The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)
Sep 9, 2025, 16:22 PM -
Patient Access Delays in Multi-Indication Medicines: A Review of Health Technology Assessment Timelines
Sep 9, 2025, 16:22 PM -
Integrating Prospective and Retrospective Real-World Data to Construct External Comparator Arms: Novel Methods and Design Considerations
Sep 9, 2025, 16:22 PM -
Stigma in People Living With Human Immunodeficiency Virus in Mizoram, Northeast India: A Prospective Observational Study
Sep 9, 2025, 16:22 PM -
What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of Early Access Pathways in Italy and France: Law 64896 vs. the French AAP
Sep 9, 2025, 16:22 PM -
The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways
Sep 9, 2025, 16:22 PM -
Mitigation of Immature and Variable Survival Data In Oncology With Additional Endpoints During Health Technology Assessment in Germany and France
Sep 9, 2025, 16:22 PM -
High Entry Costs Slower Growth: A Nationwide Register Study on Newly Reimbursed Biologic Medicines in Finland 2011-2021
Sep 9, 2025, 16:22 PM -
Reducing Premature Cancer Mortality Through Early Stage Treatment: A Markov Model Analysis of Pembrolizumab Across Four Tumor Types
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life (HRQoL) and Its Associated Factors among Chinese Gout Patients: Baseline Findings From a Survey Study
Sep 9, 2025, 16:22 PM -
Changes in Medical Technology Availability in Europe Between 2000 and 2020
Sep 9, 2025, 16:22 PM -
Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study
Sep 9, 2025, 16:22 PM